Nature13d
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
The Financial Express13d
Novo Nordisk to seek regulatory approval for obesity drug early 2026
(Image Credits: PIxabay) Novo Nordisk on Wednesday announced that it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next ...
AOL.co.uk13d
Wegovy obesity drug sales more than double but set to slow
Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo Nordisk predicted ... a prescription weight loss injection, surged to 19.9 billion ...
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Novo doubles down on next-gen weight loss therapy despite early setback
Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...
London Evening Standard13d
Wegovy obesity drug sales more than double but set to slow
Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo Nordisk predicted ...
NBC 6 South Florida13d
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Both Novo Nordisk and Eli Lilly's current weight loss treatments are administered via injection ... including its hotly anticipated experimental CagriSema treatment. Late-stage CagriSema trial ...